Acer Therapeutics — Investor Presentation (June 2023)
26 slides from Acer Therapeutics's investor presentation, Jun 26, 2023
Slide 1: Corporate Presentation June 26, 2023
Corporate Presentation June 26, 2023 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: The Acer story: mission, difference and goal
Provide transformative treatments with a human touch to underserved or overlooked patients with rare and life-threatening diseases Identify and develop treatments where science can be applied in new ways for use in diseases with high unmet need Develop and deliver life -changing therapies to patient
Slide 4: Acer Management team
Acer Management team Chris schelling Chief Executive officer & Founder Adrian quartel, md Chief medical officer Harry palmin Chief financial officer Bernie paul Chief people officer Don joseph, Jd Chief legal officer John klopp Chief technical officer Tanya hayden Chief operating officer Jeff davis
Slide 5: Commercial and late-stage pipeline
Program Indication Phase 1 Phase 2 Phase 3 Approved Expected Milestones Urea Cycle Disorders1 Approved in US; drug availability anticipated early July 2023$ EDSIVO™ (celiprolol) Vascular Ehlers-Danlos Syndrome (COL3A1+) H1 2024: Full trial enrollment$ Commercial and late-stage pipeline 1 OLPRUVA™ (s
Slide 6: OLPRUVA (sodium phenylbutyrate) for oral suspension
Full Prescribing Information: https://www.acertx.com/OLPRUVA/PI.pdf OLPRUVATM (sodium phenylbutyrate) for oral suspension
Slide 7: OLPRUVA highlights
highlights $ Subject to additional capital 1 https://www.clinicaltrials.gov/study/NCT01948427?term=thrive%20study%20horizon&rank=1 2 Data on file 3 https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-first-quarter-2023-financial 4 https://www.das.nh
Slide 8: UCDs: Disease Overview
UCDs: DISEASE Overview Urea Cycle Disorders (UCDs) are a group of rare, genetic disorders caused by mutations that result in a deficiency of one of the six enzymes or two transporters of the urea cycle These enzymes are responsible for removing ammonia from the bloodstream Reproduced from: http://up
Slide 9: UCDs: Mechanism of action
UCDs: Mechanism of action Nitrogen Binding Agents Alternative pathway treatment diverts nitrogen from the urea cycle to alternate routes of excretion Nitrogen binding agents, containing phenylbutyrate, are all metabolized to phenylacetate (PAA) PAA is the active moiety – it combines with glutamine,
Slide 10: Unmet need – efficacy
Unmet need – efficacy THRIVE Observational study1 collected data on patients with UCDs Over first three years of follow-up, patients on both Ravicti® (GPB) and Buphenyl® (NaPB): Had mean ammonia levels ≥ Upper Limit of Normal (ULN) Comparable percentage of patients had a hyperammonemic crisis in bot
Slide 11: Unmet need – treatment adherence
Mean Relative Attribute Importance for UCD Treatment Adherence in a Discrete Choice Exercise1,2 1 ACER-sponsored, IRB-approved quantitative research study employing discrete choice study design. 2 Data on file. Qualitative Interviews with Leading UCD Centers Uncovered the Mid-Day Dose as a Driver of
Slide 12: Novel Formulation
NOVEL Formulation OLPRUVA™ is a proprietary and novel formulation of NaPB powder that has shown bioequivalence to existing NaPB powder but with a pH-sensitive polymer coating that is designed to minimize dissolution of the coating for up to 5 minutes after preparation1 Polymer Coat (inactive pH-sens
Slide 13: Nitrogen Scavenger Differentiation
Nitrogen Scavenger Differentiation1 Phenylbutyrate Formulations OLPRUVA™ Ravicti® Buphenyl® Pheburane® Efficacy / Safety in UCDs ✓ ✓ ✓ ✓ Formulation Dual-coated oral pellets Clear Oily Liquid Powder or Tablets Single-coated oral pellets Palatability Up to 5 minutes Tasteless Bitter Taste Up to 10 se
Slide 14: Commercial Strategy
Commercial Strategy Unmet need and desire for new treatment options OLPRUVA™ is differentiated, dual coated, packaged in portable single dose envelopes Robust patient services program to support patients & caregivers Customized exclusive pharmacy approach to facilitate patient access to care Best in
Slide 15: Disrupting an Established UCD Market in U.S.
DISRUPTING AN ESTABLISHED UCD MARKET in U.S. Projected Prevalence1 ~ 2,100 Diagnosed Patients2 ~ 1,100 Patients Treated with Phenylbutyrate2 (Ravicti®, Buphenyl®, generics) ~ 800 Market share for nitrogen binding agents2 ~ 85% Ravicti® ~ 15% Buphenyl® or generic NaPB Ravicti® & Buphenyl® U.S. Net Re
Slide 16: OLPRUVA Price & Reimbursement
OLPRUVA™ Price & Reimbursement Acer believes pricing strategy will offer UCD patients a new treatment option at an approximately 50% discount to the current WAC price per gram of Ravicti® OLPRUVA™ pricing strategy informed by thorough market research and input received from advocacy organizations, f
Slide 17: Lifecycle Opportunities
Acer intends to explore additional lifecycle opportunities for OLPRUVA™ (sodium phenylbutyrate) in various disorders where clinical proof of concept data exists$: Maple Syrup Urine Disease (MSUD) Pyruvate Dehydrogenase Complex Deficiency (PCDC) Rare pediatric epilepsies Various liver disorders Lifec
Slide 18: Intellectual property and exclusivity
Intellectual property and exclusivity Orange Book Listed Patents: US Pat. Nos. 11,154,521 and 11,433,041 directed to formulations/compositions of matter US Pat. No. 11,202,767 directed to methods of use (UCD) Expiration date for OB patents is 10/17/2036 MSUD US Pat. Nos. 9,078,865 and 10,092,532 dir
Slide 19: EDSIVO (celiprolol) for COL3A1-positive vEDS
A selective adrenergic modulator (SAM) for the potential treatment of patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS) (celiprolol) EDSIVOTM
Slide 20: Vascular Ehlers-Danlos Syndrome COL3A1+
VASCULAR EHLERS-DANLOS SYNDROME COL3A1+ vEDS Prevalence: Between 5,000 to 10,000 COL3A1+ vEDS patients in US5 Median US Survival: 51 years of age1 Risk: Arterial rupture or dissection events occur in ~25% of patients before the age of 20, but increase to ~90% of patients by age 401 1 Pepin, et al. S
Slide 21: BBEST Trial: COL3A1+ Subpopulation
BBEST Trial: COL3A1+ Subpopulation Primary Endpoint Primary + Secondary Endpoints 0 12 24 36 48 60 72 Number at risk/events Celiprolol Control 13 13/1 12/2 9/2 8/2 2/2 20 19/2 15/6 11/9 4/11 3/11 11/3 9/3 8/3 2/3 16/5 9/12 6/14 3/14 2/14 p=0.0406 p=0.0167 time (months) Figure 3: Kaplan-Meier curves
Slide 22: Statistically-significant efficacy
Statistically-significant Efficacy: Between 2000 and 2017, 144 patients (100% COL3A1+) were included in this study Patients were normotensive (A) Patients not treated with celiprolol had a significantly worse survival outcome than treated patients: Overall survival was 80.7% (95% CI: 67.8% to 93.6%)
Slide 23: Pivotal Phase 3 trial: enrolling patients
pivotal phase 3 trial: enrolling patients $ Additional capital required to conduct and complete the planned pivotal Phase 3 trial of EDSIVO™ beyond Q4 2022 Decentralized Study of Celiprolol on vEDS-related Event Reduction (DiSCOVER) Trial A Phase 3, U.S.-based, randomized, double-blind, decentralize
Slide 24: Intellectual property and Exclusivity
Intellectual property and Exclusivity Patents Title: Method of Providing Celiprolol Therapy to a Patient Issued patent #11,523,997 – approximate expiration 12/2038 Claims direct to methods of treating vEDS Priority date is 12/21/2017 Assigned to AP-HP and Université Paris Descartes – Acer has exclus
Slide 25: Financial overview
Financial overview Capitalization as of June 22, 2023 CASH POSITION as of march 31, 2023 $6.4M +$0.4M gross proceeds from ATM sales in Q2 2023 +$1.0M gross proceeds from promissory note with Chris Schelling, CEO & Founder* Cash runway into early Q3 2023 24.5M Shares of common stock outstanding 33.9M
Slide 26: Thank You
Thank You www.acertx.com
Acer Therapeutics — Investor Presentation (June 2023) on 6ix